Abstracts

Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors

28 April 2020/in Abstracts /by circlek

Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors.
Tsimberidou A.M., Beer P., Bendall J., Dow J., King J., McElwaine-Johnn H. and Wistuba I.I.
Abstract CT151. American Association for Cancer Research Virtual Annual Meeting I; April 27-28 2020.

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma

10 December 2019/in Abstracts /by circlek

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma.
Nastoupil L.J., Neelapu S.S., Davis E., Samaniego F., Fowler N.H., Westin J.R., Lee H.J., Wang M., Hagemeister F.B., Cecil A.R.L., Dow J., McHale D., Silva F., Ward P., Yavari A., Shuttleworth S.J.; and Beer P.
Abstract 4099. 61st American Society of Hematology Annual Meeting and Exposition; December 7-10 2019; Orlando, Florida (FL), USA

Targeting PI3K pathway in ibrutinib resistant diffuse large B-cell lymphoma

1 April 2017/in Abstracts, Publications /by circlek

Targeting PI3K pathway in ibrutinib resistant diffuse large B-cell lymphoma.
Jain N., Seghal L., Shuttleworth S.J., Samaniego F.
Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2366.

Pre-Clinical Evaluation of the PI3K-p110ß/δ Inhibitor KA2237 in Mantle Cell Lymphoma

3 December 2016/in Abstracts, Publications /by circlek

Pre-Clinical Evaluation of the PI3K-p110ß/δ Inhibitor KA2237 in Mantle Cell Lymphoma.
Huang S., Nastoupil L.J., Guo H., Bell T., Ahmed M., Li C.J., Wang J., Liu Y., Zhang V., Kim C.R., Boyle J.N., Lorence E.A., Lam L.T., Chen Z., Zhang H., Shuttleworth S.J., Nomie K., Wang M., Zhang L.
Abstract 1837. 58th ASH Annual Meeting and Exposition, San Diego, CA, December 3-6 2016.

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity (Mainz)

10 May 2016/in Abstracts, Publications /by circlek

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity.
Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finnemore D., Gatland A., Haque K., Lensun L., Roitt S., Rogers H., Silva F.A., Ward P., Whale A., Shuttleworth S.J.
Abstract 207. 14th CIMT Annual Meeting, Mainz, Germany, May 10-12, 2016.

Media Centre